| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | OSR Health, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| Fr | OSR Health: Unabhängiger Wirtschaftsprüfer Shinhan legt Mandat nieder | - | Investing.com Deutsch | ||
| Fr | OSR Health, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| OSR HEALTH Aktie jetzt für 0€ handeln | |||||
| Fr | OSR Health, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11. | OSR Health, Inc.: OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes | 372 | ACCESS Newswire | Note purchase targeted to close by December 31, 2026; roadmap update on OSRK reverse takeover discussions, OTCQB uplisting and VXM01 manuscript BELLEVUE, WA / ACCESS Newswire / November 6, 2026 / OSR... ► Artikel lesen | |
| 02.11. | OSR Health, Inc.: OSR Health Board Authorizes Management to Engage with Potential Acquirer of OSRK for Reverse Takeover | 462 | ACCESS Newswire | Potential reverse takeover is a key pillar of plan to return portfolio to a national exchange; OSR Health also pursuing OTCQB uplisting BELLEVUE, WA / ACCESS Newswire / November 2, 2026 / OSR Health... ► Artikel lesen | |
| 28.10. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.10. | OSR Health, Inc.: OSR Health Provides Shareholder Update Following Nasdaq Panel Decision | 483 | ACCESS Newswire | Company evaluating options to regain compliance; further update expected by November 6, 2026; $15 million VXM01 funding mechanism remains in place; committed to continuing Shareholder Loyalty Program... ► Artikel lesen | |
| 16.10. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.08. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc. | 750 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report... ► Artikel lesen | |
| 21.08. | OSR Health, Inc.: OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission | 671 | ACCESS Newswire | The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc.... ► Artikel lesen | |
| 19.08. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.08. | OSR Health faces Nasdaq delisting over bid-price rule | 1 | Seeking Alpha | ||
| 19.08. | OSR Health droht NASDAQ-Delisting nach Verstoß gegen Mindestkurs-Anforderung | 1 | Investing.com Deutsch | ||
| 19.08. | Nasdaq to delist OSR Health after bid price compliance failure | 1 | Investing.com | ||
| 19.08. | OSR Health, Inc.: OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal | 1.562 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination")... ► Artikel lesen | |
| 19.08. | OSR Health, Inc.: OSR Health Sees Global Shareholder Momentum at Critical Inflection Point | 802 | ACCESS Newswire | Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health... ► Artikel lesen | |
| 14.08. | OSR Health, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,800 | +7,63 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| CYTOMX THERAPEUTICS | 1,778 | +3,40 % | CytomX auf der Jefferies Global Healthcare Conference: EpCAM-Programm gewinnt an Dynamik | ||
| CAPRICOR | 7,342 | +0,30 % | Capricor, Regenxbio among gainers as White House pulls Trump's FDA pick | ||
| CORMEDIX | 4,237 | +3,47 % | CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates | ||
| MINERVA NEUROSCIENCES | 1,970 | -1,30 % | Minerva Neurosciences, Inc. - 8-K, Current Report | ||
| REPLIMUNE | 18,235 | +1,05 % | Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update | TUDRIQEV in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,396 | 0,00 % | Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic | Shareholder approval and settlement and delivery of the capital increases related to the Acquisition
The Acquisition marks a major milestone in Valerio's strategy to build a leading integrated... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,646 | -0,37 % | Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) | SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 25,880 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Alto Neuroscience | ||
| CERO THERAPEUTICS | - | - | SRX Global Inc: SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies | SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate,... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? |